Vystar Corporation · OTC:VYST
Vystar — Investor Presentation (November 2009)
17 slides from Vystar's investor presentation, Nov 12, 2009
Slide 1: Vystar Investor Presentation November 2009
Vystar Investor Presentation NOVEMBER 2009
Slide 2: Why Vytex NRL?
Why Vytex NRL? Latex Allergy Concerns 3%* general population 17% healthcare workers 10% condom users Global Environmental Awareness Vytex: all natural, renewable resource Increased use petroleum-based synthetics Human carcinogenicity/ toxicity Proven Raw Material 40,000+ products made with natural r
Slide 3: Large Global Marketplace ($2.6B)
1.6% 22.4K Mexico US Europe 4.2% 59K US Europe 6.8% 60K US SE Asia India 12.5% 75K SE Asia India 35.8% 504K SE Asia India US Potential: 1.3 million metric tonnes annually (2010) Source: International Rubber Study Group, 2006 Large Global Marketplace ($2.6B) Gloves Threads Foams Other Dip Carpet Adhe
Slide 4: Vytex NRL Technology
Antunes et al. 2002 Mat Chem Phys 76:243-249 3 Crystals Generated in Distilled Water NRL Technology Vytex technology uses aluminum hydroxide to remove proteins Proteins and 3 crystals and impurities removed during centrifugation
Slide 5: Protein removal process with aluminum hydroxide
Protein Al(OH)3 crystal Field latex containing water soluble protein Solid Al(OH)3 Protein-adsorbed Al(OH)3 Protein-adsorbed Al(OH)3 Recovery & Recycling Skim layer Centrifugation
Slide 6: Vytex: An Adaptive Technology
Vytex: An Adaptive Technology Latex production Malaysia/Thailand India Guatemala
Slide 7: The Accomplishments and Future of Vystar
The Accomplishments and Future of Vystar - R & D Technical Regulatory Line Extensions Process Improvements to Reduce COGS Advanced Material Testing to Enhance Value Clinical Studies: Peer Reviewed and Published - - Industry Leadership ASTM Category 5 Global Participation in Key Industry Conferences
Slide 8: Management Team
Management Team Extensive sales, marketing and advertising management experience B2B and B2C Successful IPO and secondary offering experience Broad regulatory and financial expertise President/CEO Executive Vice President, Business Development and Marketing , Vice President, Technical Sales , Acting
Slide 9: Board of Directors
Board of Directors Broad experience in capital markets Extensive experience in OTC trading Community bank start-up expertise Entrepreneurial success Proven leadership across diverse markets and industries William R. Doyle, President/CEO, Chairman of the Board Directors CEO, Medicraft, Inc. Founder/O
Slide 10: Technical and Clinical Advisors
Technical Catharine C. Calkins-Burke, Ph.D Ranjit K. Matthan, Ph.D, KA Prevulcanised P Ltd. Quan-Tec Air, Inc.; formerly Mayo Foundation Jasmine Elastomerics Selvaraj V M Muthuraja, Stratoshift Technologies, Sdn Bhd Clinical formerly Shands at University of Florida , UCLA Medical Center formerly Ohi
Slide 11: Market Pricing Trends
@ Bmp rat by Na. acne yc? ‘twa nF sig Spat 208 Market Pricing Trends Cortiged Latex "CENTEX vs Ried Sched Sheets Na 3 S . HoH toy iH ‘ HAH HNN iH . A WE LA . LN ate at \ Jat \ Ene ame & yaa 8 328 # vystar
Slide 12: Financial Projections
Financial Projections THE FOLLOWING PROJECTIONS ARE FORWARD-LOOKING STATEMENTS. WE MAY NOT ACTUALLY ACHIEVE THE PROJECTIONS DISCLOSED AND YOU SHOULD NOT PLACE UNDUE RELIANCE UPON SUCH FORWARD-LOOKING STATEMENTS. ACTUAL RESULTS COULD DIFFER MATERIALLY FROM SUCH PROJECTIONS. IN OUR PRIVATE PLACEMENT M
Slide 13: 2009 Projections
2009 Projections Vystar Corporation FY 2009 Actual Results Projected Q1 Q2 Q3 Q4 Total Net Product Sales $ 11 $ 1 $ 6 $ 32 $ 50 Licensing Revenue - - - - - Total Net Revenue 11 1 6 32 50 Gross Margin - Product 3 (1) - 6 8 Gross Margin - Licensing - - - - - Operating expenses 511 560 485 474 2,030 Ne
Slide 14: 2010 Projections
2010 Projections Vystar Corporation FY 2010 Projected Results Q1 Q2 Q3 Q4 Total Net Product Sales $ 74 $ 123 $ 233 $ 225 $ 655 Licensing Revenue 17 87 413 499 1,016 Total Net Revenue 91 210 646 724 1,671 Gross Margin - Product 20 33 59 56 168 Gross Margin - Licensing 17 87 413 499 1,016 Operating ex
Slide 15: 2011 Projections
2011 Projections Vystar Corporation FY 2011 Projected Results Q1 Q2 Q3 Q4 Total Net Product Sales $ - $ - $ - $ - $ - Licensing Revenue 954 1,178 1,637 1,876 5,645 Total Net Revenue 954 1,178 1,637 1,876 5,645 Gross Margin - Product - - - - - Gross Margin - Licensing 944 1,166 1,620 1,858 5,588 Oper
Slide 16: Vystar Offering
Vystar Offering (Refer to PPM) Offer Up to 1,000,000 Shares of Common Stock and Warrants to Purchase up to 1,000,000 Shares of Common Stock Offering Offer Total Shares Outstanding Offer Price Offering Price $2.00 per Share $2,000,000 Warrants 500,000 at $1.50/share Exercisable within 12 months 500,0
Slide 17: Why Invest in Vystar?
Why Invest in Vystar? Large Global Market 40,000 products made with natural rubber latex $2.6B market Fully Commercialized Address Allergenicity Concerns Virtually undetectable levels of antigenic protein Endorsed by American Latex Allergy Association Green Footprint All natural, renewable resource